Kinetics

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
torsdag, maj 9, 2024
Chicago Medical School, Sale, University, Patient, Rutgers University, ATS, Alopecia areata, Kinetics, Skin, European Patent Convention, Research, MD, Doctor of Philosophy, Conference, KOL, Potential, ADS, Week, Patent, Data, Dupilumab, University of Rochester, Translational medicine, International Examiner, Magnetic resonance, Atopic dermatitis, Harvard Medical School, ASLN, TREK, Clutch (eggs), Interim, Biology, American Thoracic Society, Associate, Emergency medicine, EPO, SAN, COPD, Pharmaceutical industry

SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.
  • Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023.
  • General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023.
  • Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.

Independent Studies Further Validate the American Rare Earths’ (ARR) Halleck Creek Project

Retrieved on: 
måndag, maj 6, 2024
Tetra, EERE, Society, Rare-earth element, Uranium, ARR, Allanite, Kinetics, Energy efficiency, ASX, Mineral, Renewable energy, Research, Primary energy, Concentrate, Silica gel, Tetra Tech, Optimism, Competent person, Virginia Tech, Temperature, Wood, Acid, Liu, REE, Thorium, Engineering

DENVER, May 06, 2024 (GLOBE NEWSWIRE) -- American Rare Earths (ASX: ARR | OTCQX: ARRNF and AMRRY) (“ARR” or the “Company”) is pleased to announce results from a metallurgical study on leaching extraction of REE from Halleck Creek ore by low temperature, direct acid leaching. The U.S. Department of Energy’s Office of Energy Efficiency and Renewable Energy (“EERE”) awarded a three-year (2022-2025) research contract to Phinix, LLC with American Rare Earth and Virginia Tech as team members. This metallurgical study was carried out by researchers at the Department of Mining and Minerals Engineering at Virginia Tech. These positive results further confirm the findings of the metallurgical testwork carried out by Wood PLC1 which were previously announced by ARR.

Key Points: 
  • Fast leaching kinetics are attributable to Halleck Creek metamict allanite structure, with 65% of REEs extracted in the first 10 minutes of leaching.
  • Halleck Creek ore is less refractory than monazite or bastnaesite, which cannot be leached using low-temperature acid tank leaching.
  • Green and Smart Mining Engineering - (Xiao and Zhang, 2024)
    High-grade rare-earth enriched Halleck Creek ore highlights its economic potential.
  • Donald Swartz, Chief Executive Officer of American Rare Earths commented:
    “We’re extremely pleased with the leaching results which further validate the recent scoping study assumptions and our optimism around the project.

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

Retrieved on: 
torsdag, maj 2, 2024
TARC, Kinetics, Research, Patient, Dupilumab, ASLN, Biology, Biomarker, Atopic dermatitis, SAN, Pharmaceutical industry

The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab.

Key Points: 
  • The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab.
  • The first part of the collaboration will focus on receptor biology and kinetics to investigate the cellular and molecular basis of eblasakimab’s potential for differentiation.
  • Under the new research collaboration, ASLAN and Zenyaku will conduct collaborative studies that will explore the biology of the IL-13 and IL-4 receptors, including the effects of biologics eblasakimab, dupilumab and lebrikizumab on each receptor subunit.
  • The results from this research collaboration will provide further insight into the differentiated receptor biology of targeting IL-13R versus IL-4R.

Eldorado Gold Reports First Quarter 2024 Financial and Operational Results; Steady Start to 2024

Retrieved on: 
torsdag, april 25, 2024
AISC, Kinetics, Olympias, Competence, Depreciation, Progress, Eldorado Gold, Ventilation, Assessment, Public expenditure, Engineering, Gold, Tax, Steel, GM, Pond, Burns, Workforce, Palladium

VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Eldorado Gold Corporation (“Eldorado”, "Eldorado Gold" or “the Company”) today reports the Company’s financial and operational results for the first quarter of 2024.

Key Points: 
  • VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Eldorado Gold Corporation (“Eldorado”, "Eldorado Gold" or “the Company”) today reports the Company’s financial and operational results for the first quarter of 2024.
  • Production and cost outlook: The Company is maintaining its 2024 annual production guidance of 505,000 to 555,000 ounces of gold.
  • The increase was driven by increased gold production and gold sales and higher average realized gold price.
  • In addition to the Operational Readiness team, as at March 31, 2024, there were over 600 personnel on site which is expected to ramp up to 1,300 during 2024.

Dinosaurs in Motion is Coming to The Henry Ford June 9 - September 8

Retrieved on: 
torsdag, april 18, 2024
Mechanics, System, Sculpture, Social media, Kinetics, Exhibition, STEAM, Innovation, Culture, Art, Robotics, Drawing

DEARBORN, Mich., April 18, 2024 /PRNewswire/ -- The Henry Ford presents Dinosaurs in Motion from June 9 to September 8 in Henery Ford Museum of American Innovation. Dinosaurs in Motion is a new, interactive, engaging STEAM (Science, Technology, Engineering, Arts & Mathematics) exhibition that is truly for visitors of all ages. This exhibition engages and educates by using 16 magnificent, fully interactive, recycled life-size metal dinosaur sculptures inspired by actual fossils.

Key Points: 
  • Dinosaurs in Motion is a new, interactive, engaging STEAM (Science, Technology, Engineering, Arts & Mathematics) exhibition that is truly for visitors of all ages.
  • This exhibition engages and educates by using 16 magnificent, fully interactive, recycled life-size metal dinosaur sculptures inspired by actual fossils.
  • Dinosaurs in Motion is an amazing blend of science, art and innovation.
  • For updates on hours, tickets and more, visit thf.org or follow The Henry Ford on social media @thehenryford.

Kinetics Noise Control Unveils Revamped Room Acoustics Website for Enhanced User Experience

Retrieved on: 
onsdag, april 10, 2024
Room acoustics, Room, Acoustics, Marketing, Navigation, Kinetics

DUBLIN, Ohio, April 10, 2024 /PRNewswire-PRWeb/ -- Kinetics Noise Control Inc. (Kinetics), a Catalyst Acoustics Group company and manufacturer of the largest selection of noise control products and solutions, announces the launch of its newly redesigned Room Acoustics website.

Key Points: 
  • Kinetics Noise Control has relaunched its Room Acoustics website with a fresh and streamlined look, featuring a modernized layout across nearly 50 pages within the prominent division.
  • DUBLIN, Ohio, April 10, 2024 /PRNewswire-PRWeb/ -- Kinetics Noise Control Inc. (Kinetics), a Catalyst Acoustics Group company and manufacturer of the largest selection of noise control products and solutions, announces the launch of its newly redesigned Room Acoustics website.
  • Key highlights of the website upgrade include:
    Enhanced User Experience: The new layout ensures a user-friendly interface, allowing visitors to effortlessly explore the diverse range of Room Acoustics products and solutions.
  • This includes informative content about the benefits and applications of Kinetics Noise Control's acclaimed Room Acoustics solutions.

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite St

Retrieved on: 
måndag, april 1, 2024
Lung cancer, Survival, Immunotherapy, Disease, Colorectal cancer, Progression-free survival, Medicine, Patient, Common, DNA, Aes, Cancer, Death, Doctor of Philosophy, Gritstone bio, MD, Kinetics, Induction chemotherapy, MSS, Circulating tumor DNA, VAF, Melanoma, PFS, Vaccine, Data, UCLA, Liver disease, Neoplasm, Pharmaceutical industry

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). The randomized, controlled, open-label study is designed to quantify the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902) in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone. Overall progression free survival (PFS) data show an early trend in benefit for GRANITE patients (HR=0.82, [95% CI, 0.34-1.67]; 62% censored) and extended PFS benefit in high-risk patients (HR=0.52 [95% CI, 0.15-1.38]; 44% censored), in whom progression occurs faster. Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms. Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).

Key Points: 
  • Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).
  • “Today's preliminary Phase 2 results are highly encouraging and represent the first randomized trial evidence, albeit early, that a personalized neoantigen-directed vaccine can potentially drive efficacy in a metastatic ‘cold’ tumor.
  • Fortunately, long-term analysis demonstrates the expected correlation of ctDNA with clinical benefit and favors GRANITE patients.
  • This analysis was performed on 44 patients who received study treatment (control and GRANITE arms) and have available baseline ctDNA data.

Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans

Retrieved on: 
måndag, april 1, 2024
CSF, Tmax, AUC, Patient, Cerebrospinal fluid, Cmax, Kinetics, APP, SILK

MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced the publication of new data from an earlier study supporting buntanetap as a translational inhibitor of amyloid precursor protein (APP) in patients with early Alzheimer’s Disease (AD).

Key Points: 
  • Buntanetap is an oral molecule that selectively binds to an iron-responsive element in the mRNA of APP and other neurotoxic proteins and inhibits their translation.
  • Through this mechanism, buntanetap was shown to decrease the production of amyloid beta (Aβ), a key hallmark in AD.
  • Here, SILK was used to measure the kinetics of APP in early AD patients and to quantify Aβ40 in CSF.
  • Notably, the analysis of adverse events demonstrated no dose-dependent effect of buntanetap compared to placebo, affirming the drug’s safety and tolerability.

Liberty Gold Reports Phase 4 Metallurgical Column Leach Results and Final Phase 5 Metallurgical Drill Assays at its Black Pine Oxide Gold Project, Idaho

Retrieved on: 
torsdag, mars 14, 2024
4C, Database, Silver, Associate, ICP, LGD, Gold, Kinetics, Carbon, TSX, PQ, OTCQX, Metallurgy, CIL, Sodium cyanide, Map, Composite

Additionally, final assay results are released on the remaining 4 metallurgical core holes drilled in 2023 to provide samples for the Phase 5 metallurgical test program.

Key Points: 
  • Additionally, final assay results are released on the remaining 4 metallurgical core holes drilled in 2023 to provide samples for the Phase 5 metallurgical test program.
  • Jon Gilligan, President & Chief Operating Officer for Liberty Gold said, “The results of this latest phase of metallurgical column testwork add key infill data to the gold recovery model at Black Pine.
  • Phase 4B and 4C composites and the pending Phase 5 variability test program filled gaps in the Black Pine resource metallurgical database.
  • Gold and silver were recovered from column leach pregnant solutions by passing it through a small (separate) column containing activated carbon.

LGM Pharma Unveils Enhanced Analytical Testing Services and Expands CDMO Portfolio with Additional Suppository Manufacturing Capabilities

Retrieved on: 
onsdag, mars 13, 2024
Other Manufacturing, Research, Packaging, Clinical Trials, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, CDMO, Growth, ATS, ICP-OES, Patient, LGM, History, ICP-MS, Kinetics, Senior, Doctor of Philosophy, Nausea, Quality, Traction, API, Operation, Fine chemical

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.

Key Points: 
  • LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.
  • With a broad array of analytical testing capabilities for small-molecule drug substances and drug products, LGM Pharma can meet the demands of large and small clients, from established pharmaceutical companies to start-ups.
  • In addition to analytical testing, the company provides comprehensive method development and validation services, as well as stability testing, including real-time and accelerated stability studies.
  • “As patient needs become increasingly diversified, the pharmaceutical industry needs CDMO partners that can provide specialized capabilities,” said Ian Gibson, Executive Vice President of Operations at LGM Pharma.